Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune DisordersRead More
With its proprietary CHO-M cell line and SUREtechnology™ protein expression platform, Selexis provides partners worldwide with stable cell lines producing virtually any recombinant therapeutic protein at a high level and with consistent quality attributes. Over the last twenty years, Selexis has expressed both classical and novel scaffolds with increased levels of secretion complexity, such as:
Here is an overview of some expressed protein formats at Selexis. Selexis has also expressed many others that remain undisclosed.
Among the 10 marketed products and 160+ clinical phase products developed with Selexis’ proprietary technology, there are many different Fc fusion proteins:
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.